LUNDBECK ACQUIRES ALDER PHARMACEUTICALS FOR $2 BILLION

https://www.fiercebiotech.com/biotech/lundbeck-pens-2b-alder-takeover-to-boost-brain-disease-pipeline

 

Does Lundbeck have an ESPP? Do reps get stock?

 

Silly boy! I needed a good laugh this morning’. The answer to your question is NO! But we do a ton of role playing, in fact, that’s all we do!! Hope you like it!

 

Sounds like a real headache to promote. That’s going to be a dog fight with Amgen, Lilly, and Teva. I can’t wait to see what the buy and bill process looks like. Lundbeck can’t even get specialty pharmacy right.

 

Buy and bill will be a nightmare, at best. Also, the B&B will totally eliminate the primary care market, and since it’s an infusion, THE PC MARKET IS DEAD. That market is huge. Since the others are once monthly injections, a nurse in a PC office can give it. Sometimes a 3 month is at a disadvantage against a 1 month because this gives the patient 2 more opportunities to interact with the office and possibly the doctors. Specialty pharmacy will be a problem as well as coverage. I am sure it’s a good drug, but longer acting is not always an advantage.

Looks like the psych reps better bring it up a notch!

 

Neuro and pain management centers are a significant portion of this market. Buy and Bill is 2nd nature to most of them. Also, it would be naive to think this product wouldn’t be used preferentially over other option since there is money to be made. Contracts that stipulate market shares to get deeper rebates, etc....Bottom line: there is room for this product. How successful depends on how aggressive Lundbeck is willing to be

 

You are right, there is room for this product. Perhaps in 30% of specialists who have access to an infusion center and are willing to do it.

Buy and bill is only profitable when there are limited options or significant data differences. Neither of which applies here.

Lundbeck paid double what this product was worth. Good luck making that up.

Northera part 2.

 

infusion is money made by the office. A self injection is not. Is a shot given by an MA profitable? Do the MAs who inject Maintena make money for the dr?

Just asking because I don’t know.

The comments on the Alder board leading up to the buyout were really positive for this molecule

 

I was interviewing at Alder before I left Lundbeck for a different company. I think the molecule is a winner. Buy and bill infusion is a big money maker for privately owned neuro offices. And from what I understand the injectables have their issues with regards to injection site pain and burning sensations. In the right patient and in the right office this is a winner. The question you have to ask yourself is do you want to be part of a sales team engaged in a primary care like dog fight. This ain’t the rare disease sale that Onfi Northera and our legacy rare disease molecules were. It’s going to be a lot of marketing messages and repetitive messaging.

 

What does PTO at Lundbeck US sites look like?

 

Since an infusion would be impossible to promote to primary care like the others, it will be barred from a huge market like others have said here on CP. Also, oral drugs in this class will soon be on the market. The market will soon be flooded! Lundbeck can’t compete with Amgen/Novartis, Lilly and Teva.

When you have a company that has a meeting to go over some minute changes in a visual aid, that company has some very real management issues.

 

PTO includes vacation, sick and personal days= 25 days a year to start plus company shut down christmas to new year's.

At 48 months we start earning five more PTO days a year.

Plus we get the usual holidays (except MLK which we should get). And if we hit revenue targets we get one additional company holiday during the July 4th week.

 

Thanks!

 

Thank you Matt!!! May I have another???

 

You get 1 extra week after 5 years not 48 months!

 

So let me get this straight. LU buys a 4th to market drug that is IV not subQ with orals on the horizon? You can tout B&B all you want from the docs standpoint but if the insurance companies say you go subQ first then LU has jumped on board to another loser. And remember, any $ the docs makes on the infusion is being paid by somebody. Only hope is that it undercuts the prices of the others. Please remember though that the same leadership is in place as when Brintellix was launched. It was during that launch that we were told the copay card is only for the 1st month. This drug (Brintellix) is so good the patients will want to pay for it themselves.

 

Also, Evaluate Pharma predicted Brintellix would be a $2 billion a year blockbuster, which anyone with half-a-brain knew was lunacy ! The migraine drug will be a colossal failure! Just like Rexulti being used for PTSD and agitation for Alzheimer’s. Just look at Dunsire’s record of ruining companies. Soon, Lundbeck will be added to the list. All of you that have stayed will regret it. You’ve have let so many opportunities pass you by, and the question is why.

 

once Biohaven launches, this infused CGRP is DOA.

I’m sure all involved will have bonuses for doing the deal, gotten elevated and be off to their next adventure while we are left holding the bag on this turd.

Smells like Northera.

 

It doesn’t really matter. Our time here is very limited. They will get rid of high salaried employees in favor for hiring employees at much lower salaries like they are doing now. Just accept it for what it is, a temporary job.

 

Let’s be honest, any job in pharma these days is a temporary job